Real-time intraoperative evaluation of implant quality and dose correction during prostate brachytherapy consistently improves target coverage using a novel image fusion and optimization program

被引:12
作者
Zelefsky, Michael J. [1 ]
Cohen, Gilad N. [1 ]
Taggar, Amandeep S. [1 ]
Kollmeier, Marisa [1 ]
McBride, Sean [1 ]
Mageras, Gig [1 ]
Zaider, Marco [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, Dept Med Phys, New York, NY 10065 USA
关键词
BIOCHEMICAL CONTROL; SEED IMPLANTATION; DOSIMETRY; CANCER; OUTCOMES;
D O I
10.1016/j.prro.2017.01.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Our purpose was to describe the process and outcome of performing postimplantation dosimetric assessment and intraoperative dose correction during prostate brachytherapy using a novel image fusion-based treatment-planning program. Methods and materials: Twenty-six consecutive patients underwent intraoperative real-time corrections of their dose distributions at the end of their permanent seed interstitial procedures. After intraoperatively planned seeds were implanted and while the patient remained in the lithotomy position, a cone beam computed tomography scan was obtained to assess adequacy of the prescription dose coverage. The implanted seed positions were automatically segmented from the cone-beam images, fused onto a new set of acquired ultrasound images, reimported into the planning system, and recontoured. Dose distributions were recalculated based upon actual implanted seed coordinates and recontoured ultrasound images and were reviewed. If any dose deficiencies within the prostate target were identified, additional needles and seeds were added. Once an implant was deemed acceptable, the procedure was completed, and anesthesia was reversed. Results: When the intraoperative ultrasound-based quality assurance assessment was performed after seed placement, the median volume receiving 100% of the dose (V100) was 93% (range, 74% to 98%). Before seed correction, 23% (6/26) of cases were noted to have <100 b90%. Based on this intraoperative assessment and replanning, additional seeds were placed into dose-deficient regions within the target to improve target dose distributions. Postcorrection, the median V100 was 97% (range, 93% to 99%). Following intraoperative dose corrections, all implants achieved V100 >90%. Conclusions: In these patients, postimplantation evaluation during the actual prostate seed implant procedure was successfully applied to determine the need for additional seeds to correct dose deficiencies before anesthesia reversal. When applied, this approach should significantly reduce intraoperative errors and chances for suboptimal dose delivery during prostate brachytherapy. (C) 2017 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:319 / 324
页数:6
相关论文
共 14 条
[1]   RADIATION DOSE PREDICTS FOR BIOCHEMICAL CONTROL IN INTERMEDIATE-RISK PROSTATE CANCER PATIENTS TREATED WITH LOW-DOSE-RATE BRACHYTHERAPY [J].
Ho, Alice Y. ;
Burri, Ryan J. ;
Cesaretti, Jamie A. ;
Stone, Nelson N. ;
Stock, Richard G. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (01) :16-22
[2]   125I reimplantation in patients with poor initial dosimetry after prostate brachytherapy [J].
Keyes, M ;
Pickles, T ;
Agranovich, A ;
Kwan, W ;
Morris, WJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01) :40-50
[3]   Whole prostate D90 and V100: A dose-response analysis of 2000 consecutive 125I monotherapy patients [J].
Morris, W. James ;
Spadinger, Ingrid ;
Keyes, Mira ;
Hamm, Jeremy ;
McKenzie, Michael ;
Pickles, Tom .
BRACHYTHERAPY, 2014, 13 (01) :32-41
[4]   A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy [J].
Potters, L ;
Cao, YJ ;
Calugaru, E ;
Torre, T ;
Fearn, P ;
Wang, XH .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 50 (03) :605-614
[5]   12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer [J].
Potters, L ;
Morgenstern, C ;
Calugaru, E ;
Fearn, P ;
Jassal, A ;
Presser, J ;
Mullen, E .
JOURNAL OF UROLOGY, 2005, 173 (05) :1562-1566
[6]   Favorable toxicity and biochemical control using real-time inverse optimization technique for prostate brachytherapy [J].
Raben, Adam ;
Rusthoven, Kyle E. ;
Sarkar, Abrihup ;
Glick, Andrew ;
Benge, Bruce ;
Jacobs, Dayee ;
Raben, David .
BRACHYTHERAPY, 2009, 8 (03) :297-303
[7]   Review of Portable CT with Assessment of a Dedicated Head CT Scanner [J].
Rumboldt, Z. ;
Huda, W. ;
All, J. W. .
AMERICAN JOURNAL OF NEURORADIOLOGY, 2009, 30 (09) :1630-1636
[8]   A dose-response study for I-125 prostate implants [J].
Stock, RG ;
Stone, NN ;
Tabert, A ;
Iannuzzi, C ;
DeWyngaert, JK .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 41 (01) :101-108
[9]   Customized dose prescription for permanent prostate brachytherapy: Insights from a multicenter analysis of dosimetry outcomes [J].
Stone, Nelson N. ;
Potters, Louis ;
Davis, Brian J. ;
Ciezki, Jay P. ;
Zelefsky, Michael J. ;
Roach, Mack ;
Fearn, Paul A. ;
Kattan, Michael W. ;
Stock, Richard G. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (05) :1472-1477
[10]   Intraoperative adaptive brachytherapy of iodine-125 prostate implants guided by C-arm cone-beam computed tomography-based dosimetry [J].
Westendorp, Hendrik ;
Hoekstra, Carel J. ;
van't Riet, Arie ;
Minken, Andre W. ;
Immerzeel, Jos J. .
BRACHYTHERAPY, 2007, 6 (04) :231-237